Literature DB >> 15886718

Reinstatement of morphine-conditioned reward is blocked by memantine.

Piotr Popik1, Malgorzata Wrobel, Adam Bisaga.   

Abstract

Protection of abstinent individuals from relapse is the main goal of drug dependence treatment. Relapse is frequently precipitated by exposure to small doses of the drug of abuse or exposure to the environment that was previously associated with the drug. Mice exposed to morphine (10 mg/kg) in a unique test-box environment display a conditioned place preference for this environment. Such preference can be extinguished by subsequent pairing of physiological saline administration with the same environment. Once extinguished, the original place preference can be reinstated after a priming dose (1-2.5 mg/kg) of morphine is given. However, mice treated with 7.5 (but not 3.75) mg/kg of memantine (the glutamate/NMDA receptor antagonist) during the extinction phase were insensitive to morphine's ability to reinstate the place preference 2 days after extinction conditionings. Effect of memantine was also observed when priming dose of morphine was given 21 days after extinction conditionings. In contrast, morphine's ability to reinstate conditioned response was not affected by treatment with 10 mg/kg of chlordiazepoxide, 0.5 mg/kg of LSD-25, or 1 mg/kg of morphine given during extinction conditionings. A separate experiment demonstrated that memantine (7.5 mg/kg) treatment did not affect learning. We show for the first time that memantine treatment during extinction conditionings may abolish the ability of drug-related cues to evoke reinstatement, suggesting that this NMDA receptor antagonist can be useful in preventing relapse in opioid dependent individuals. Neuropsychopharmacology (2006) 31, 160-170. doi:10.1038/sj.npp.1300760; published online 11 May 2005.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 15886718     DOI: 10.1038/sj.npp.1300760

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  30 in total

1.  Post-retrieval beta-adrenergic receptor blockade: effects on extinction and reconsolidation of cocaine-cue memories.

Authors:  Ashley N Fricks-Gleason; John F Marshall
Journal:  Learn Mem       Date:  2008-08-26       Impact factor: 2.460

2.  A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.

Authors:  Adam Bisaga; Maria A Sullivan; Wendy Y Cheng; Kenneth M Carpenter; John J Mariani; Frances R Levin; Wilfrid N Raby; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2011-06-28       Impact factor: 4.492

3.  A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.

Authors:  Adam Bisaga; Maria A Sullivan; Andrew Glass; Kaitlyn Mishlen; Kenneth M Carpenter; John J Mariani; Frances R Levin; Edward V Nunes
Journal:  J Subst Abuse Treat       Date:  2014-01-17

Review 4.  Stress modulation of reconsolidation.

Authors:  Irit Akirav; Mouna Maroun
Journal:  Psychopharmacology (Berl)       Date:  2012-10-06       Impact factor: 4.530

5.  Memantine fails to facilitate partial cigarette deprivation in smokers--no role of Memantine in the treatment of nicotine dependency?

Authors:  N Thuerauf; J Lunkenheimer; B Lunkenheimer; W Sperling; S Bleich; M Schlabeck; J Wiltfang; J Kornhuber
Journal:  J Neural Transm (Vienna)       Date:  2006-10-18       Impact factor: 3.575

Review 6.  Reconsolidation of drug memories.

Authors:  Barbara A Sorg
Journal:  Neurosci Biobehav Rev       Date:  2012-02-10       Impact factor: 8.989

7.  Common influences of non-competitive NMDA receptor antagonists on the consolidation and reconsolidation of cocaine-cue memory.

Authors:  Yasaman Alaghband; John F Marshall
Journal:  Psychopharmacology (Berl)       Date:  2012-07-25       Impact factor: 4.530

8.  Daily memantine treatment blunts hedonic response to sucrose in rats.

Authors:  Adriana Galistu; Paolo S D'Aquila
Journal:  Psychopharmacology (Berl)       Date:  2019-08-14       Impact factor: 4.530

9.  Effects of the NMDA receptor antagonist memantine on the expression and development of acute opiate dependence as assessed by withdrawal-potentiated startle and hyperalgesia.

Authors:  Andrew C Harris; Patrick E Rothwell; Jonathan C Gewirtz
Journal:  Psychopharmacology (Berl)       Date:  2007-11-16       Impact factor: 4.530

10.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.